SLAS Highlights: Opening Keynote Spotlights Novel Target in Genomically Unstable Tumors
BOSTON—The recent SLAS conference in Boston showcased a pivotal keynote by Dr. Serena Silver, chief scientific officer of Accent Therapeutics, emphasizing the KIF18A protein as a promising target for precision oncology. This focus aligns with the increasing integration of automation in drug discovery and bioprocessing, underscoring the industry’s shift towards high-throughput methodologies. Dr. Silver’s insights…









